With new regulations taking effect this fall and more advanced technologies now available, the state of clinical development of new drugs and devices is definitely changing for the better.On November 1, ...
Company: PerkinElmer Informatics
Dr. Daniel C. Weaver is the Manager of Scientific Computing at Array BioPharma, Inc. in Boulder, Colorado. He received his doctorate in developmental genetics from the University of Colorado, Boulder under the direction of Dr. William B. Wood where he studied patterning in early development. Prior to and during his Ph.D. work, Dr. Weaver led various software development projects, and since receiving his doctorate, he has led scientific software development efforts for genetic network modeling, human genetics research and cheminformatics.
Email Daniel C. Weaver, Ph.D.Daniel C. Weaver, Ph.D.
Your Full Name:
- In this demo DXP file, the scientist is analyzing multi-plexed ELISA data obtained from clinical trails Subject's blood samples. By integrating traditional clinical labs data with translational research labs data and clinical therapeutic response assessments, the scientist is able to derive novel insights into the relationship between the amount of drug in the Subject's blood, the degree of biological effect, and clinical response.
Translational Medicine Overview
TIBCO Spotfire for Clinical Research
Originally presented at Bio-IT World April 10, 2013
Dan Weaver's presentation at the 2011 CambridgeSoft Conference and User Meeting in London.